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Putative breast cancer driver 
mutations in TBX3 cause impaired 
transcriptional repression
Kathrin Fischer and Gert O. Pflugfelder*
Institute of Genetics, Mainz University, Mainz, Germany
The closely related T-box transcription factors TBX2 and TBX3 are frequently overex-
pressed in melanoma and various types of human cancers, in particular, breast cancer. 
The overexpression of TBX2 and TBX3 can have several cellular effects, among them 
suppression of senescence, promotion of epithelial–mesenchymal transition, and inva-
sive cell motility. In contrast, loss of function of TBX3 and most other human T-box 
genes causes developmental haploinsufficiency syndromes. Stephens and colleagues 
(1), by exome sequencing of breast tumor samples, identified five different mutations in 
TBX3, all affecting the DNA-binding T-domain. One in-frame deletion of a single amino 
acid, p.N212delN, was observed twice. Due to the clustering of these mutations to the 
T-domain and for statistical reasons, TBX3 was inferred to be a driver gene in breast 
cancer. Since mutations in the T-domain generally cause loss of function and because 
the tumorigenic action of TBX3 has generally been attributed to overexpression, we 
determined whether the putative driver mutations had loss- or gain-of-function proper-
ties. We tested two in-frame deletions, one missense, and one frameshift mutant protein 
for DNA-binding in vitro, and for target gene repression in cell culture. In addition, we 
performed an in  silico analysis of somatic TBX mutations in breast cancer, collected 
in The Cancer Genome Atlas (TCGA). Both the experimental and the in silico analysis 
indicate that the observed mutations predominantly cause loss of TBX3 function.
Keywords: TBX3, breast cancer, somatic mutations, p21, frameshift mutation, in-frame deletion, driver mutation
inTrODUcTiOn
Cancer is assumed to progress by a type of Darwinian evolution that operates at the cellular rather 
than the organismic level. Mutations arise in an approximately random fashion. Those that increase 
the fitness of the affected cell relative to its neighbors (driver mutations) will be positively selected 
(and vice versa). Most mutations are neutral (passenger mutations) or deleterious from the perspec-
tive of the cancer cell. New sequencing techniques allow increasingly fast and affordable acquisition 
of DNA sequence information from cancer tissue, either of the exome or the complete genome. 
Genes that in a mutated or misexpressed form can promote cancer development are operationally 
defined as cancer genes. Most cancer mutations act dominantly (oncogenes) indicating gain-of-
function, or possibly haploinsufficiency. Less than 10% are assumed to be tumor suppressors, requir-
ing homozygosity of the mutant allele for the tumor promoting effect. The discrimination between 
driver and passenger mutations is not trivial (2, 3). It is plausible to assume and is born out by the 
mutation pattern of bona fide oncogenes that, in the category of point mutations, only particular 
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missense mutations are able to cause an activated gene product. 
On the other hand, tumor suppressor genes can be inactivated 
by a higher proportion of missense mutations, in addition to 
nonsense and frameshift mutations, in a large part of the protein 
coding region. Vogelstein and colleagues proposed a rule of the 
thumb according to which >20% of all mutations in a gene must 
be recurrent missense mutations in particular positions to qualify 
it as an oncogene, while a tumor suppressor gene should contain 
>20% of inactivating mutations (3). It should be added that only 
mutations in tissues in which these genes are active should be 
taken into account.
The two closely related T-box transcription factors TBX2 and 
TBX3 are considered oncogenes because they are frequently 
overexpressed in melanoma (4–6) and various types of human 
cancer, such as breast, bladder, liver, and pancreas carcinoma 
(7–11). These correlative data are supported by direct biological 
evidence. TBX2/3 can contribute to transformation by suppress-
ing senescence and anoikis (5, 12–16). TBX2/3 can promote 
epithelial–mesenchymal transition (EMT) and invasive cell 
behavior in melanoma and breast cancer cells (6, 10, 17, 18) and 
in heterospecific epithelia (19). TBX2/3 may also contribute to 
breast cancer growth by promoting proliferation of cancer stem-
like cells (20, 21). Part of this may be attributed to the induction of 
polyploidy and resistance to anti-cancer drugs (cisplatin), which 
can be caused by TBX2 overexpression (22, 23). TBX2/3 can also 
stimulate proliferation (17, 21, 24–28). Cell lines overexpressing 
TBX2 can show TBX2 addiction (24). TBX2/TBX3 represses 
expression from the long control region (LCR) of human papil-
loma viruses HPV16 and 18, the main causative agents of cervical 
cancer. LCR repression is enhanced by interaction of TBX2/3 
with the HPV L2 minor capsid protein. L2 and TBX2 were found 
to colocalize in tissue sections of cervical intraepithelial neoplasia 
(29).
TBX2 and TBX3 are members of the Tbx2 subfamily of T-box 
transcription factors (30). Tbx2 (12, 31–34) and Tbx3 (35–37) 
are predominantly transcriptional repressors. Recently a role of 
TBX3 (and TBX5) also in splicing has been recognized (38, 39). 
Tbx2 and Tbx3 are important developmental regulators control-
ling, among others, the development of heart, kidney, limbs, 
lung, the visual system, and mammary tissue (8, 40–47). Null 
mutations in most members of the human Tbx gene family cause 
heritable haploinsufficiency syndromes. TBX3 haploinsufficiency 
is the cause of ulnar-mammary syndrome (48, 49). Some of the 
oncogenic properties of TBX2/3 appear conserved in evolution. 
In Drosophila, the only Tbx2 subfamily gene is optomotor-blind 
(omb, FlyBase: bifid, bi) (50). Overexpression of omb or TBX2 
in an epithelium of the developing fly, the wing imaginal disk, 
causes two types of cellular motility: migration in the plane of 
the epithelium and basal delamination with penetration of the 
basal membrane (19). Omb also controls cell proliferation in a 
context-dependent manner (51, 52).
Although Tbx2 and Tbx3 are often both expressed in the 
development of a given organ, their expression at tissue and cellu-
lar level can diverge in time and space. During mouse embryonic 
breast development, Tbx2 and Tbx3 are co-expressed in mesen-
chyme but only Tbx3 is expressed in epithelial tissue (mammary 
placode and branching mammary duct epithelium). Tbx2 is 
not expressed in postnatal stages (53), whereas Tbx3 remains 
expressed throughout breast development (54, 55). Although 
TBX2 and TBX3 share many properties at the molecular and 
cell biological level, they can be functionally distinct, at least in 
melanoma cells (17, 56).
According to current knowledge based on studies in cell cul-
ture and experimental animals, the tumorigenic action of TBX2/3 
appears predominantly caused by gain-of-function (transcrip-
tional upregulation or gene amplification). This is supported by 
the finding that TBX2 or TBX3 are overexpressed/amplified in 
melanoma and various types of cancer and that the degree of 
overexpression correlates with invasiveness, distant metastasis, 
and poor prognosis (11, 57–59).
In recent exome analyses of somatic mutations in breast 
cancer, several mutations in TBX3 were identified. Stephens and 
colleagues in an analysis of 350 breast cancer samples found 
three short deletions (in each case resulting in the in-frame 
deletion of one amino acid; N212 was deleted in two cancers) 
and three truncating mutations. All changes clustered within 50 
amino acids of the TBX3 T-domain. Based on the high relative 
mutation frequency and the apparent non-random clustering 
of the mutation sites, TBX3 was considered a driver gene (1). 
Due to the recurrence of ΔN212, TBX3 also fulfils the driver 
gene definition of Vogelstein et al. (3). Kandoth et al. analyzed 
the exome of 12 tumor types present in The Cancer Genome 
Atlas (TCGA). Using the MuSIC tool (60) they identified TBX3 
as “significantly mutated gene” (SMG) with an increased muta-
tion rate relative to background, in particular in breast cancer. 
ΔN212 was also identified in their analysis of 763 breast cancer 
specimen (61).
We here investigate the molecular function of four putative 
driver mutations identified by Stephens et  al. (1) and Kandoth 
et  al. (61) in order to determine whether they have gain- or 
loss-of-function properties in vitro and in vivo. We, furthermore, 
analyze the occurrence and distribution of TBX3 mutations in 
breast cancer in relation to other TBX genes and to other tumors.
MaTerials anD MeThODs
Protein sequence alignment
Human TBX protein sequences were aligned with Clustal 
Omega (62). The following sequences were used (gene name 
and Ensembl protein number): EOMES ENST00000449599, 
T ENST00000296946, TBR1 ENST00000389554, TBX1 
ENST00000332710, TBX2 ENST00000240328, TBX3 
ENST00000349155, TBX4, ENST00000240335, TBX5 
ENST00000310346, TBX6 ENST00000395224, TBX10 
ENST00000335385, TBX15 ENST00000207157, TBX18 
ENST00000369663, TBX19 ENST00000367821, TBX20 
ENST00000408931, TBX21 ENST00000177694, TBX22 
ENST00000373294.
Plasmid constructions
Primer sequences are provided in Table S5 in Supplementary 
Material. All unmodified oligonucleotides were synthesized by 
Sigma-Aldrich, Taufkirchen, Germany.
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Construction of cell culture TBX3 expression clones: starting 
clone TBX3-3xFLAG/pENTR/D-TOPO was constructed by A. 
Legler based on a TBX3 +  2a cDNA clone (ImaGenes, Berlin, 
Germany). Mutations were introduced using the QuikChange® II 
XL Site-Directed Mutagenesis Kit (Agilent, Waldbronn, Germany) 
and primers 1379/1380 for TBX3dm (G129A/R130S), 1562/1563 
for Y163fs2*, 1784/1785 for H187Y, 1564/1565 for T210delT, 
and 1560/1561 for N212delN. The C-terminally FLAG-tagged 
sequences were transferred to pT-Rex-DEST30 using Gateway® 
LR Clonase™ II Enzyme Mix (Invitrogen, Darmstadt, Germany).
Construction of bacterial expression clones: DNA encoding 
the first 342 amino acids of TBX3 (normal or mutant sequence) 
were amplified by linker PCR from the corresponding TBX3-
3xFLAG/pENTR/D-TOPO clones. Primers 1879 and 1880 con-
taining BamHI and SalI restriction sites, respectively, were used 
for amplification. These sites were used to clone the amplificate 
into pGEX-2TK (GE Healthcare).
Construction of p21-FLuc (firefly luciferase) expression vec-
tor: 2335 bp from the promoter region of the p21 gene (CDKN1A, 
ENSG00000124762) were amplified from a genomic clone 
(obtained from G. Spoden) by linker PCR using primers 1808 and 
1323. The SV40 promoter was removed from the pGL3-control 
vector (Promega, Mannheim, Germany) by KpnI/HindIII digest 
and replaced by the p21 promoter fragment by T4 DNA ligase 
ligation.
Bacterial expression and Purification of 
TBX3 Mutant Proteins
GST-TBX3(1–342) in pGEX-2TK and its mutant derivates were 
expressed in Escherichia coli BL21DE3 (New England Biolabs) by 
isopropyl-β-d-thiogalactopyranosid (IPTG) induction. Cleared 
sonified cell lysate was chromatographed on glutathione agarose 
(Cube Biotech, Monheim, Germany) following the company’s 
instructions1. Protein concentration in eluate fractions were 
measured by Bradford assay (Roti-Quant, Carl Roth, Karlsruhe, 
Germany).
electrophoretic Mobility shift assay of 
gsT-TBX3 Protein Mutants
Electrophoretic mobility shift assays were performed using a 
double-stranded 5′ digoxigenin (DIG)-labeled 24 base oligonu-
cleotide (AATTTCACACCT AGGTGTGAAATT) containing 
the Brachyury consensus target site (synthesized by MWG 
Biotech/Eurofins, Ebersberg, Germany). GST-tagged proteins 
were incubated with DIG-oligo at 15°C for 1 h in electrophoretic 
mobility shift assay (EMSA) buffer [20 mM HEPES, 100 mM KCl, 
1 mM DTT, 0.25 mM EDTA, 0.01% NP-40, 1 mM MgCl2, 8% 
glycerol, 100 μg/ml BSA, 1 mg/ml Poly(dI-dC)], then loaded on a 
6% acrylamide gel and run in standard 1× TBE, 1% glycerol. The 
gel was blotted to a positively charged Nylon membrane (Roche, 
Mannheim, Germany) in a Mini-PROTEAN Tetra Cell (Bio-Rad) 
in Tris glycin buffer. Protein–DNA complexes were fixed to the 
membrane by UV crosslinking. The DIG label was detected by 
DIG luminescent detection (Roche, Mannheim, Germany).
1 http://www.cube-biotech.com/protocols
normalization of repression activity to 
Protein concentration
TBX3 and its mutant derivatives differed in concentration in 
transfected cells, even though they were expressed from the 
same type of vector. This departure from uniform expression 
contributes to differences in repressive activity between the TBX3 
variants. Repression was calculated from FLuc activity values by 
normalizing these values to the control (=100%). These values 
were subtracted from 100, yielding 0 repression for the control, 
and values between 0 and 100 for TBX3 and its derivatives. 
The dose response curves of p21-Luc repression by TBX3 and 
TBX3dm were approximately linear in the range between 8.3 
and 25 ng with about 0.5% change in repression per nanogram 
of expression vector. Using the measured relative protein levels 
(Western blot), we extrapolated repression by the mutant proteins 
to the level observed for normal TBX3.
cell culture and Transfection
COS-7 cells were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) (Biochrom AG, Berlin; Germany) containing 10% fetal 
calf serum (FCS, Biochrom AG) and 1% penicillin (10,000 U/ml)/
streptomycin (10,000 μg/ml) (PS, Biochrom AG). Twenty-four 
hours before transfection 105 cell/ml were cultured in DMEM/
FCS in the absence of antibiotics and grown at 37°C, 5% CO2 
to 70–90% confluence. Transient transfection was performed 
with 3  μl/ml FuGENE® HD Transfection Reagent (Promega, 
Mannheim, Germany). In cycloheximide inhibition experiments, 
cycloheximide (Sigma-Aldrich, Taufkirchen, Germany) was 
added to 25 μg/ml.
Measurement of Firefly luciferase activity
In the 96-well format, cells (100 μl) were transfected with 25 ng of 
reporter vector and 25 ng of TBX expression vector. Forty-eight 
hours after transfection, the supernatant was removed, cells were 
washed with PBS and then lysed for 30 min at room temperature 
in Passive Lysis Buffer (Promega, Mannheim, Germany). Twenty 
microliters of lysate were measured after addition of 40  μl 
luciferase agent (Luciferase Assay System, Promega) in white 
96-well microplates (Nunc/Thermo Scientific, 136101, Schwerte, 
Germany) in a GloMax® 96 Microplate Luminometer (Promega). 
Premeasurement delay was 2 s, the measurement took 10 s.
Western Blot analysis
Bacterial cells or partly purified protein fractions were supplied 
with 6× Laemmli sample buffer to a final concentration of 1× 
sample buffer (63). COS-7 cells were transfected for 48  h (12-
well plates) with TBX expression constructs, trypsinized, and 
resuspended in PBS. After pelleting (5  min, 13,000  rpm in an 
Eppendorf microcentrifuge) cells were resuspended in 25–50 μl 
urea lysis buffer (7 M urea, 2 M thiourea, 5 mM DTT, 2% Chaps, 
0.01% Proteinase Inhibitor Cocktail (Sigma-Aldrich P8340), 
1 mM PMSF). Cells were lysed for 30 min on ice. Protein con-
centration was determined with a Bradford assay (Roti-Quant, 
Roth, Karlsruhe, Germany). Appropriate volumes of cell lysate 
were combined with 6× Laemmli sample buffer and loaded on 
an 8 or 10% SDS gel. PageRuler™ Prestained Protein Ladder 
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(Thermo Scientific) was used to calibrate gel mobilities. Blotting 
to a PVDF membrane (Amersham Hybond™-P, GE Healthcare, 
München, Germany) and detection procedure was as described 
above in the EMSA protocol. FLAG epitope was detected with 
mouse monoclonal M2 (1:1000–2000), alpha-tubulin with mouse 
monclonal B5-1-2 (1:1000) (both Sigma-Aldrich). HRP-tagged 
goat anti-mouse IgG was used as a secondary antibody (1:10,000, 
Jackson ImmunoResearch, Dianova, Hamburg, Germany).
For pixel density analysis of fluorographs, several exposures 
were taken and analyzed using the ImageJ program2.
rna isolation and Quantitative Pcr
RNA was isolated 48  h after transient transfection using 
RNeasy kit (QIAGEN, Hilden, Germany) following the com-
pany’s instructions. cDNA was synthesized using Superscript 
III First-Strand Synthesis System for RT-PCR (Invitrogen) and 
oligo-dT primers according to instructions. qPCR reactions were 
performed in MicroAmp® Fast Optical 96-Well Reaction Plates 
with Barcode (Life Technologies, 4346906) in a StepOnePlus™ 
Real Time PCR-System (Applied Biosystems, Darmstadt). Two 
hundred nanograms of cDNA, 0.1 μl each of forward and reverse 
primers (20 μM), and 10 μl of SYBR Green mix (KAPA SYBR 
FAST ABI Prism, Peqlab, Erlangen, Germany) were combined in 
a final volume of 20 μl. Cycling conditions were 3 s 95°C, 30 s 
60°C followed by a melting curve analysis of the PCR product. 
Data were analyzed with the StepOnePlus™ software. Data were 
normalized to beta-actin (primers 1760/1761). TBX3 expression 
was measured with primers 1924/1925, p21 expression with 
primers 1772/1773 (see Table S5 in Supplementary Material).
statistical analysis
Statistical analysis of cell culture experimental data was performed 
with GraphPad Prism (Version 5). Inflated p-values due to multiple 
comparisons between groups were adjusted by the Bonferroni–
Holm procedure (64). The following significance levels were used: 
*<0.05, **<0.01, and ***<0.001. Significance assessment of TBX 
mutation type distributions in the ICGC database was done by 
calculating the respective probability for observing the actual or a 
more extreme distribution of the mutations between the different 
TBX3 domains. For this, an urn model was used with the number 
of mutations representing the number of draws. Since mutations 
can repeatedly occur at the same locus (“drawing with replace-
ment”), a binomial distribution with the ratio of domain length to 
total TBX3 length as expectation value under the null hypothesis 
was chosen. The resulting p-values were doubled to correspond 
to two-tailed tests. Calculations were performed with SAS® for 
Windows® version 9.4 (SAS Institute Inc., Cary, NC, USA).
resUlTs
Degree of conservation of Mutated amino 
acids in TBX3
Amino acid conservation is used as one parameter to assess 
whether a mutation is likely to impart driver properties to the 
2 http://imagej.nih.gov/ij/
affected protein (65). Stephens and colleagues observed full 
conservation of the TBX3 residues, which were mutated in their 
collection of breast cancer sequences among orthologous animal 
Tbx3 proteins (1). Because of the strong phylogenetic conser-
vation of the T-domain, we used a more stringent alignment 
containing all paralogous human TBX proteins. This alignment 
(Figure  1) shows that the mutation p.T210delT affects a fully 
conserved residue.
p.N212delN, which was identified in three cases of breast 
cancer (1, 61), affects a position that is largely conserved, only 
TBX6 showing a deviating serine. However, in Brachyury (T) and 
in TBX19, this residue is lacking, suggesting that it is not essential 
for Tbx function.
The mutation p.H187Y, a potential driver mutation identi-
fied in two cases of breast cancer, affects a fully conserved 
histidine (61).
Kandoth et al., in their analysis of 12 different cancer types, 
identified 33 further missense mutations in TBX3, 12 of which 
(36%) map to the T-domain [as defined by Porsch et al. (66)]. The 
T-domain makes up 27% of the TBX3 protein (743 amino acids), 
indicating only a slight enrichment of missense mutations in this 
part of the protein. In addition to p.H187Y, two further breast 
cancer mutations map to the TBX3 T-domain in the data set 
analyzed by Kandoth et al.: p.L112F and p.W113R. Both residues 
are fully conserved among human TBX proteins.
In addition to missense mutations, Stephens and colleagues 
described three frameshift mutations in TBX3 whose breakpoints 
cluster within 30 amino acids of the T-domain (1). As an example 
of a truncated protein, we also analyzed p.Y163fs2*.
Dna-Binding Properties of Mutant 
Proteins
We tested DNA binding of the bacterially expressed mutant 
proteins by EMSA. For all variants, we used an N-terminal 
fragment (1–342) in order to reduce degradation to which the 
full-length protein is susceptible. The fragment was derived from 
the long TBX3 + 2a splice form (67). The 1–342 fragment extends 
C-terminally for some 50 amino acids beyond the T-domain. 
The protein length of 342 was chosen, because the paralogous 
proteins TBX2 and TBX3 start to diverge more strongly beyond 
this position. All fragments contained an N-terminal GST tag 
(glutathione S-transferase) for affinity purification. Mutations 
were introduced by site specific mutagenesis. The mutant proteins 
were expressed in E. coli and subsequently purified by glutathione 
affinity chromatography. Figure 2A shows that all proteins were 
obtained with similar purity. A Western blot of SDS gel-separated 
proteins (Figure 2B) shows that the fast band at around 30 kDa, 
which is present in all preparations, was also immunoreactive 
to anti-GST. The molecular mass of GST is 26.7 kDa, indicating 
that GST is partly cleaved from TBX3 very close to the TBX3 
N-terminus, possibly in the protease cleavage site, which is present 
in pGEX-expressed proteins at the junction between GST and 
cargo. The intensity of the GST-TBX3 fusion bands was measured 
(Figure 2C) so that equivalent amounts of normal and mutant 
GST-TBX3 fragments could be tested by EMSA for binding to 
a palindromic Tbx consensus oligonucleotide (68). The normal 
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protein produced a single strong shift band. The binding affinities 
of p.N212delN and p.T210delT were slightly reduced compared 
to wild type (Figure 2D). The reduced affinity of p.T210delT and 
p.N212delN was not statistically significant (Figure  2E), even 
though we observed the same pattern of attenuated binding in all 
EMSA gels. Binding of p.H187Y was only obvious when the gel 
was overexposed. No DNA binding was observed with p.Y163fs2* 
(Figures  2D–F) and p.G129A/R130S (TBX3dm, engineered as 
a binding-deficient mutant, see below) (Figure 2F) under these 
conditions.
reporter gene repression in Transfected 
cells: The role of Dna Binding
TBX3 was first implicated in tumorigenesis because it was 
found to suppress cellular senescence, could immortalize pri-
mary embryonic fibroblasts, and could transform this cell type 
in combination with Myc or activated Ras (13, 16, 35). In the 
suppression of cellular senescence, transcriptional repression of 
cyclin-dependent kinase inhibitor 1A (p21) and 2A (in human: 
p14ARF; in mouse: p19ARF) has a key role. The repression by 
TBX3 is direct and repression activity of TBX2/3 variants can be 
tested on p21 promoter constructs in transient transfection assays 
(32, 69). Since the presumptive TBX3 driver mutations affected 
DNA binding, we first tested whether p21-Luc could still be 
repressed by a DNA-binding-deficient mutant. We used the TBX3 
double mutant p.G129A, R130S (TBX3dm). Single mutations in 
homologous position have previously been shown to cause loss 
of DNA binding in other Tbx proteins [TBX5: G80R (70), Omb: 
R355K (71), see also TBX2 (R122E, R123E) (72)].
In COS-7 cells, the p21-Luc promoter construct was repressed 
by TBX3 in a dose-dependent fashion. Normal TBX3 caused 
80–90% repression of reporter activity at our highest concentra-
tion of TBX vector (25  ng/assay). TBX3dm generally reached 
60% repression (Figure 3A). Both proteins at 25 ng approached 
saturation. The dose-dependence curves show that TBX3 reached 
60% repression already at a concentration of <1 ng/assay, while 
FigUre 1 | human TBX proteins in alignment with TBX3. About one-sixth of the T-box, containing the mutations under consideration, is shown (TBX3 from 
185 to 216). The complete TBX3 T-box encompasses residues 104–288 (66). Fully conserved amino acids are marked gray and T-box positions containing similar 
amino acids are green. In the top line, the three investigated mutations are marked red.
TBX3dm required 25  ng/assay to reach this degree of repres-
sion. The data indicate that part of the repression caused by 
TBX3 does not require DNA binding. The mutant p.Y163fs2*, 
which lacks both an intact DNA-binding domain and the entire 
C-terminal domain, failed to repress the p21 reporter (Figure S1 
in Supplementary Material).
TBX3dm protein abundance in transfected cells reproducibly 
was less than that of normal TBX3 (as determined by anti-FLAG 
immunoblotting: 0.59 ± 0.08, n = 6) (Figures 3B,C and 4B). The 
repression activity of TBX3dm at 25 ng (60% repression) should, 
thus, be compared to TBX3 at 15 ng (85% repression) (Figure 3A). 
Because of the shallow slope in this part of the dose–response 
curve, TBX3 remains a more effective inhibitor than TBX3dm 
even when adjusted for differences in protein abundance.
reporter gene repression in Transfected 
cells: The effect of Presumptive Driver 
Mutations
We used the p21-Luciferase assay to determine how TBX3 
activity was affected by the putative driver mutations. Full-
length proteins, C-terminally tagged with a FLAG tag were 
used, with the exception of p.Y163fs2* where the untagged 
truncated protein was tested. As observed above (Figure 3A), 
the DNA-binding-defective double mutant TBX3dm repressed 
p21-Luc 1.5- to 2-fold. A similar repression was observed for 
the other binding-deficient mutant p.Y163fs2*. Surprisingly, 
the mutants that were less impaired in DNA binding, p.H187Y 
and p.T210delT, did not differ significantly from TBX3dm. 
However, the repression activity of p.N212delN was close to that 
of TBX3 (Figure 4A). While the differences in p21-Luc repres-
sion between TBXdm, Y163fs2*, H187Y, and T210delT were 
small, the same relative order was observed in all experiments.
We did not normalize the data in Figure 4A to the expression 
of a co-transfected vector because we noted that the expression of 
Renilla luciferase from the normalization vector pGL4.74 (pRL-
TK, Promega) was also modulated by TBX3 and its mutants. This 
FigUre 2 | Bacterial expression and Dna binding of mutant TBX3 proteins. (a) GST-TBX3 protein variants after purification by glutathione affinity 
chromatography. Equal amounts of peak eluate protein were separated on a 10% SDS gel and stained with Coomassie Blue. Normal and point mutant protein 
fractions yielded a full-length band of 70 kDa [calculated molecular weight of the GST-TBX3(1–342) fusion protein is 65.4 kDa] and a band with ~30 kDa mobility. 
GST-TBX3(fs163fs2*) migrated with the expected mobility of ~48 kDa. (B) Anti-GST Western blot. A gel as shown in (a) was blotted and probed with anti-GST. Both 
the 70 and the 30-kDa band reacted with the antibody. Additional bands visible in the Coomassie-stained gel between 65 and 80 kDa were not immunoreactive. (c) 
Quantification of fusion band expression of the blot shown in (B). (D) Electrophoretic mobility shift assay of GST-TBX3 protein variants. Equal amounts of fusion 
protein as determined in (c) were employed. The GST-TBX3(1–342) wildtypic fusion protein effectively shifted the consensus T-box binding element oligonucleotide 
(arrowhead), the point mutant derivatives T210delT and N212delN were slightly less efficient, H187Y yielded only a faint signal (arrow). (e) Quantification of 
shift-band intensity. The amount of oligonucleotide shifted by TBX3 was set to 1 (n = 4). (n = not detected, ns = not significant) (F) EMSA comparison of p.Y163fs2* 
and the negative control mutant TBX3dm. Control is shift oligonucleotide alone.
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also holds for other normalization constructs (29). As noted above 
for TBX3dm, the expression level for mutant proteins differed in 
a characteristic way from normal TBX3. TBX3dm, H187Y, and 
T210delT were less abundant than TBX3 (~2×, ~3×, and ~1.5×, 
respectively), while N212delN was always more abundant (up to 
1.5×) (Figure 4B). We normalized the repression to a uniform 
protein concentration (see Materials and Methods). This correc-
tion led to stronger apparent repression activity of the proteins 
expressed at a lower level than TBX3, and vice versa. Overall, the 
effect of normalization was small (Figure 4C). The normalization 
could not be performed for the untagged p.Y163fs2*.
repression of endogenous p21 by TBX3 
and Mutant Derivatives
Transiently transfected reporter constructs cannot be expected 
to render the regulatory complexity of the endogenous gene. 
We, therefore, determined by real time qPCR how TBX3 and its 
mutant derivatives affected endogenous p21 transcription. TBX3 
repressed endogenous p21 although to a lesser degree than the 
p21-Luc reporter (Figure 5). Of the four tested mutants, only 
the DNA-binding-deficient TBX3dm did not repress the endog-
enous gene. The three putative driver mutant proteins contain-
ing point mutations were as repressive on endogenous p21 as 
normal TBX3 (the untagged frame shift mutant p.Y163fs2* 
was not tested). This still held when the p21 expression values 
were normalized to protein abundance. The repressive effect 
of the TBX3 mutants, thus, differed between endogenous p21 
and the transfected p21-Luc reporter. Mutant TBX3 proteins 
with residual DNA-binding affinity (H187Y, T210delT, and 
N212delN) effectively repressed the endogenous p21 gene but 
TBX3dm failed to do so. However, on transfected p21-Luc, 
TBX3dm repressed transcription about twofold, similar to the 
FigUre 4 | repression of a p21-luc reporter by TBX3 and mutant 
derivatives. (a) The repression of the p21-Luc reporter was measured 
with 25 ng of expression vector encoding the normal or mutant TBX3 
proteins. For control, empty expression vector was transfected. Luc 
expression is in arbitrary units. The Luc data from six independent 
experiments were normalized to TBX3 (=1). Average and SD are shown. 
TBX3dm, Y163fs2*, H187Y, and T210delT were significantly weaker 
repressors than normal TBX3 but also differed significantly from control. 
The mutant N212delN did not differ significantly from normal TBX3; hence, 
was an effective repressor. (B) Quantification of protein expression. Protein 
expression was visualized by Western blot of cell extract and FLAG 
immunodetection. Protein load was controlled with anti-alpha-tubulin.  
(c) Normalization of Luc repression by TBX3 and mutant derivatives to their 
respective protein concentration. The luciferase activity values of one 
experiment, for which the protein expression data are shown in (B), were 
normalized to the control (=100%). To obtain repression data, these values 
were subtracted from 100 (0% repression in the control) and shown as 
black columns (error bars are SD, n = 6 technical replicates). The values 
after normalization to the different protein levels (see Materials and 
Methods) are presented by white columns.
FigUre 3 | repression of p21-luc reporter by TBX3 and the Dna 
binding-deficient mutant TBX3dm. (a) Comparison of p21-Luc repression 
by TBX3 and TBX3dm in transfected COS-7 cells. In all assays, a total of 
25 ng of the expression vector was used, with a varying ratio of empty to 
TBX vector. In the control, 25 ng of empty expression vector was transfected. 
Repression of the p21-Luc reporter was measured at six different 
concentrations of TBX3 or TBX3dm. Luc activity in the absence of TBX3 was 
defined as 0 repression (n = 3). (B) Comparison of TBX3 and TBX3dm 
expression. TBX3dm expression is shown in a dilution series of its expression 
vector. Protein expression was visualized by Western blot of cell extract and 
FLAG immunodetection. Protein load was controlled with anti-alpha-tubulin. 
(c) Relative expression of TBX3 and TBX3dm. COS-7 cells were transfected 
with 25 ng expression vector (n = 6).
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other strongly DNA-binding-defective mutant proteins H187Y 
and T210delT (Figure 4C).
Differential expression of Mutant TBX3 
Proteins
The expression level of the five FLAG-tagged TBX3 variant 
proteins, as determined by Western blotting, differed in a char-
acteristic manner (Figure 4B). This pattern was observed in five 
independent transfection experiments and, thus, was unlikely to 
be produced by stochastic fluctuations.
All TBX3 variants were expressed from the same expression 
vector. The different protein accumulation which we observed, 
therefore, could be due to differential protein stability. We 
determined protein stability of TBX3, H187Y, and N212delN 
by blocking protein synthesis with cycloheximide (73) and 
following protein abundance over 12–24 h. Protein levels were 
normalized to alpha-tubulin, which appeared stable over this 
period. The TBX3 level declined to 0.73 within 12 h (SD = 0.18, 
n =  6), whereas H187Y declined to 0.2 (Figures 6A,B), i.e., at 
least threefold faster than the normal protein. N212delN before 
addition of cycoheximide was slightly more abundant than TBX3 
FigUre 5 | repression of the endogenous p21 gene by TBX3 and 
mutant derivatives. COS-7 cells were transfected with 50 ng of expression 
vector encoding TBX3 or its mutants (the empty vector was transfected in 
the control experiment). RNA was isolated and the level of p21 transcripts 
was determined by real-time qPCR. The p21 level is normalized to the control 
(1.0, black columns, error bars are SDs, n = 3 with three technical replicates 
each). To correct for differences in the amount of TBX protein, an adjustment 
was performed as described in Section “Materials and Methods” (white 
columns). Only TBX3dm differed significantly in p21 repression from normal 
TBX3, the three single mutants did not.
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and was similarly stable (Figures 6C,D); N212delN declined to 
0.74 within 12 h (SD =  0.26, n =  3). Thus, differential protein 
stability did not account for the higher steady state abundance 
of N212delN. Therefore, we also determined the transcript level 
of normal and mutant TBX3 in transfected cells by real-time 
PCR. Surprisingly, transcript abundance of H187Y was slightly 
lower and that of N212delN significantly higher than that of 
TBX3, indicating that difference in RNA production or turnover 
contributes to the differences in protein levels (Figure 6E).
statistical considerations of somatic 
TBX3 Mutations in cancer Tissues
The somatic mutation database of the International Cancer 
Genome Consortium (ICGC)3 lists 149 somatic mutations in 
TBX3. In order to draw inferences about the relevance of these 
mutations, we used the mutations in the other human TBX genes 
as reference. Table S1 in Supplementary Material shows the 
distribution of somatic mutations in the 16 human TBX genes in 
different cancer tissues. The breast cancer data (BRCA-US) derive 
from TCGA project in which somatic mutations from about 
thousand donor tissues were analyzed (61, 74). It is obvious that 
in breast cancer, TBX3 has the highest number of mutations of 
all TBX genes.
In Table 1, these numbers are normalized to the total number 
of mutations in a given TBX gene across the different cancer types. 
This normalization allows the comparison between different TBX 
3 https://dcc.icgc.org, release 17
genes. In breast cancer, TBX3 is the most frequently mutated of all 
TBX genes (17.6%). The mutation rate averaged over all 16 TBX 
genes is 3.6% corresponding to a 4.7-fold enrichment for TBX3.
In Table S2 in Supplementary Material, the mutation numbers 
are normalized to the number of mutations in the entire set of 
TBX genes. This serves to normalize mutations in a given gene 
to the average mutation frequency in a particular cancer tissue 
and to the different number of tissue samples analyzed. Breast 
cancer was conspicuous because 29.3% of all TBX mutations in 
this tissue were found in TBX3. This is not due to TBX3 being 
a larger mutational target. TBX3 (13.9  kb) is twofold smaller 
than the average of TBX genes (29.9 kb). Table 1 and Table S2 in 
Supplementary Material are sorted by the number of TBX muta-
tions identified in a given cancer project. Results at the top of 
these tables are more significant than those at the bottom.
Human TBX gene size varies by more than 17-fold (between 
6 and 106  kb), whereas variation in protein length is <2-fold. 
The ICGC data collection also contains intronic mutations such 
that mutation number per gene will be influenced by gene size. 
Table 2 gives the number of breast cancer mutations that affect 
the open reading frame (ORF) of TBX genes. Five types of muta-
tions were considered: frameshift, missense, synonymous, stop 
codon gained, and in-frame deletion. Compared to the average 
occurrence of a particular mutation type in TBX genes, frameshift 
and in-frame deletion mutations in TBX3 were strongly (12× and 
16×) and missense mutations moderately (3×) enriched. This 
enrichment is characteristic for breast cancer. When the entire 
ICGC data set was analyzed for TBX3 ORF mutations (ratio of 
complete ICGC to BRCA-US dataset ~12/1), 21 frameshift muta-
tions were found, 15 of which arose in breast cancer (8.5-fold 
enrichment). This concentration of frameshift TBX3 ORF muta-
tions in breast cancer is highly non-random (p < 10−7). Similarly, 
two of five in-frame deletions occurred in the BRCA-US data 
set. The preponderance of these particular types of mutations in 
TBX3 versus the other TBX genes points to an important role of 
TBX3 in breast cancer progression.
The position of breast cancer frameshift mutations in TBX3 
was highly non-random. Fourteen of 15 mutations lie in the 
N-terminal half of TBX3, 10 lie in the T-domain (Figure 7). Both 
distributions are highly unlikely to arise by chance (p <  10−4 
and <2 × 10−3, respectively). The frameshift mutation, which we 
analyzed (Y163fs2*) and identified in a different cancer project 
(1), also fell into this pattern.
If breast cancer progression is associated with mutations that 
cause loss of DNA binding, this should also be reflected in TBX3 
missense mutations. In the BRCA-US data set, eight independent 
missense mutations in TBX3 were identified, H187Y occurring 
twice. Four of these lie in the T-domain [L112F, W113R, H187Y 
(2×)] (Table S3 in Supplementary Material). We expect that 
mutations of fully conserved residues of the T-domain are more 
likely to disturb DNA binding than mutations of non-conserved 
residues. L112F, W113R, and H187Y are fully conserved residues 
in all 16 human TBX proteins. We showed that DNA binding 
was severely compromised by H187Y (Figure  2C). A muta-
tion affecting the tryptophane corresponding to TBX3 W113 
was identified in TBX22 in a patient with X-linked cleft palate 
(W102C). The mutant TBX22 protein is inactive in DNA binding 
FigUre 6 | Protein stability and transcript abundance of TBX3 and mutant derivatives. COS-7 cells were transfected with 50 ng of expression vector 
encoding TBX3 or its mutants. Twenty-four hours after transfection cycloheximide (CHX) was added to 25 μg/ml. Cells were lysed at the indicated time points. 
Protein level was quantified by Western blot of cell extract and FLAG bioluminescence immunodetection. Protein load was controlled with anti-alpha-tubulin. (a,B) 
TBX3 and H187Y, (c,D) TBX3 and N212delN. (e) Quantification of TBX3 transcript levels by real time qPCR. COS-7 cells were transfected with 25 ng of expression 
vector encoding TBX3 or its mutants (the empty vector was transfected in the control experiment). RNA was isolated 48 h after transfection and analyzed. The data 
are normalized to TBX3. No TBX3 transcription was detected (nd) in cells transfected with empty vector. The higher level of N212delN RNA relative to normal TBX3 
was statistically significant (n = 3).
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(75). In the BRCA-US data set, 13 missense mutations lie in the 
T-domain of non-TBX3 TBX genes. Of these, three affect fully 
conserved (23%), two functionally conserved (15%), and eight 
(62%) non-conserved residues. This closely corresponds to the 
distribution of conservation categories (25, 21, and 64%, respec-
tively). The enrichment for conserved residues as targets of 
missense mutations in TBX3 supports the idea that loss of TBX3 
T-box function is relevant for breast cancer progression. There 
was also a trend for conservation of the C-terminal TBX3 breast 
cancer mutations. About one-quarter of C-terminal residues are 
conserved between mammalian Tbx2 and Tbx3 proteins. Three 
of four C-terminal TBX3 mutation affected such conserved 
amino acids.
DiscUssiOn
Protein structural considerations of the 
investigated Putative Driver Mutations
Coll and colleagues have analyzed the structure of the TBX3 
T-domain in complex with a 20-bp palindromic target sequence 
(76). In this structure, N212 is part of a loop that connects the 
short β-strands e and e′. The length of this loop varies in different 
Tbx proteins. As shown in Figure 1, the members of the Tbr1 
subfamily (TBR1, TBX21, and EOMES) (77) contain an insertion 
of three amino acids in this loop. Drosophila Omb, too, the insect 
ortholog of Tbx3, contains such an insertion. Importantly, the 
e–e′ loop also contains the 20 amino acids insertion present in 
the splice variant TBX3 + 2a. TBX3 + 2a is the product on an 
alternative splice form, which contains the additional 60 bp exon 
2a which is found in all mammalian Tbx3 genes (69). Hoogaars 
and colleagues found no influence of the additional 20 amino 
acids on DNA-binding in vitro, on the interaction with Nkx2–5, 
and on the repressor function of Tbx3 on two natural promot-
ers in transfected cells. Similarly, no difference was noted in the 
interaction with Sox4 (78). The issue is, however, controversial 
(79, 80). Our data show that shortening of the e–e′ loop had little 
effect on DNA-binding in vitro and target gene repression. While 
N212 is a strongly conserved residue among T-box proteins 
(mammalian members of the Tbx6 subfamily carry serine at this 
position, Figure 1), members of the T subfamily (Brachury and 
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TBX19) lack the corresponding am
ino acid. Th
is suggests that 
N
212 is not essential for T-box function.
In the X-ray structure of the TBX3–D
N
A
 com
plex, T210 is 
part of the short β-strand e encom
passing am
ino acids 208–211. 
Th
ese four am
ino acids are com
pletely conserved in the T-box 
protein fam
ily (Figure 1). K
208 and N
211 interact w
ith the 
target D
N
A
 both in TBX3 and in Xenopus Brachyury (76, 81). 
A
 structural change in this protein strand is, therefore, expected 
to have functional consequences. In TBX19, even a conserva-
tive m
utation of the lysine, corresponding to K
208 in TBX3, to 
arginine abolishes D
N
A
 binding and target gene activation (82). 
Th
e m
utation T209I in Tbx20 (T209 in Tbx20 corresponds to 
T210 in TBX3, see Figure 1) causes a reduction in the activation 
of an endogenous target gene in an ex vivo assay at low
 concen-
tration of the m
utant protein. H
ow
ever, at high concentration 
the m
utant protein is as effective as norm
al Tbx20 (83). In this 
respect, Tbx20–T209I and TBX3–T210delT appear sim
ilar. 
T210delT, too, reduces but does not elim
inate affi
nity for T-box 
target sequences.
TaBle 1 | relative frequency of TBX mutations in icgc somatic cancer mutation data base.
eOM 
es
T TBr 
1
TBX 1 TBX 2 TBX 3 TBX 4 TBX 5 TBX 6 TBX 
10
TBX 
15
TBX 
18
TBX 
19
TBX 
20
TBX 
21
TBX 
22
average Total
Liver cancer – RIKEN, JP 8.6 9.2 10.5 0 5.9 7.2 9.9 13.3 2.4 5.2 17.1 16 16 22.8 11.7 14.7 10.66 396
Esophageal adenocarcinoma – UK 6.5 9.2 9.5 9.7 1 3.9 10.5 16.4 1.2 2.1 16.1 14 10.7 16.3 9.6 0 8.54 335
Pancreatic cancer – AU 12.9 8.4 9.5 11.8 7.8 11.1 11.7 13.1 6 0 0 5.9 9.3 12.6 12.8 12.3 9.08 255
Skin cutaneous melanoma – TCGA, US 12.9 10.7 14.3 6.5 7.8 5.9 7 3.8 13.3 18.8 8.9 4.8 10 8.5 8.5 6.7 9.28 239
Ovarian cancer – AU 4.3 4.6 1 12.9 2.9 6.5 6.4 8.7 3.6 8.3 12.9 9.4 5.3 6.8 3.2 8.6 6.59 235
Gastric adenocarcinoma – TCGA, US 7.5 11.5 11.4 5.4 9.8 5.2 4.7 4.9 19.3 10.4 0.7 4.4 6.7 1 6.4 4.9 7.14 160
Liver cancer – FR 1.1 1.5 1.9 2.2 2.9 0.7 4.7 2.3 7.2 3.1 5.1 14.7 5.3 0.7 6.4 2.5 3.89 146
Colon adenocarcinoma – TCGA, US 8.6 7.6 7.6 6.5 5.9 5.2 7 3.3 13.3 7.3 2.6 3.1 3.3 3.1 4.3 3.1 5.74 137
Liver cancer – NCC, JP 7.5 2.3 6.7 9.7 3.9 2.6 4.1 5.6 3.6 2.1 2.3 3.1 4.7 4.1 5.3 4.9 4.53 124
Renal cell cancer – EU/FR 1.1 1.5 2.9 5.4 8.8 1.3 8.8 4.1 1.2 2.1 4.4 5.9 3.3 3.4 5.3 1.2 3.79 124
Lung squamous cell carcinoma – TCGA, US 4.3 6.9 4.8 0 5.9 7.8 0.6 2.3 2.4 4.2 0.5 3.5 3.3 2.7 5.3 8 3.91 101
Pancreatic cancer – CA 3.2 3.1 1.9 3.2 3.9 3.9 1.8 4.1 1.2 1 4 1.8 9.3 2 4.3 1.8 3.16 95
Breast cancer – TCGA, US 3.2 3.1 3.8 2.2 2.9 17.6 2.3 2.1 1.2 5.2 0.9 1.5 2.7 1.4 2.1 6.1 3.64 92
Oral cancer – IN 2.2 0 1 0 0 0 0.6 0.3 0 8.3 13.3 0 0 0.3 0 0 1.63 71
Breast triple negative/lobular cancer – UK 0 0.8 0 9.7 1 2.6 3.5 1.8 1.2 1 2.1 2.2 3.3 3.1 1.1 0.6 2.13 65
Malignant lymphoma – DE 1.1 1.5 1 1.1 1 4.6 2.3 2.8 2.4 1 1.6 1.3 1.3 1 0 6.7 1.92 60
Lung cancer – KR 0 4.6 1 2.2 6.9 0.7 0 2.1 3.6 1 1.6 0.9 1.3 2 0 5.5 2.09 57
Thyroid cancer – SA 1.1 1.5 3.8 4.3 7.8 1.3 1.8 1.3 6 4.2 0.7 0.4 0 0.3 3.2 1.8 2.47 50
Pancreatic cancer endocrine neoplasms – AU 0 0.8 0 1.1 1 1.3 1.8 1 1.2 0 1.2 1.8 0 2.4 0 1.2 0.93 35
Bladder urothelial cancer – TCGA, US 2.2 3.1 1.9 0 2.9 2.6 1.8 1.8 2.4 1 0.5 0 0.7 0 0 0.6 1.34 32
Pediatric brain cancer – DE 0 0 1 0 0 0 1.2 1 0 0 1.2 2.2 1.3 0.7 0 1.8 0.65 29
Acute myeloid leukemia – KR 0 2.3 0 2.2 2 0 1.8 0 0 5.2 0.2 0.2 0 0 5.3 0 1.20 22
Rectum adenocarcinoma – TCGA, US 0 0.8 1.9 1.1 3.9 1.3 1.2 0 0 2.1 0.2 0.2 0 0.7 1.1 1.8 1.02 22
Brain glioblastoma multiforme – TCGA, US 1.1 1.5 1 1.1 0 0 0 1 1.2 0 0.2 0.4 0 0.3 1.1 1.8 0.67 18
Prostate adenocarcinoma – TCGA, US 2.2 0 0 0 0 2.6 0 0.3 0 0 0 0.9 0.7 1.4 0 0 0.51 16
Brain lower grade glioma – TCGA, US 0 0.8 0 1.1 2 0 0 0.5 0 2.1 0.2 0.2 0 0.3 0 0.6 0.49 12
Kidney renal clear cell carcinoma – TCGA, US 2.2 0 1 0 0 0 1.2 0 3.6 0 0 0.2 1.3 0 1.1 0 0.66 12
Bladder cancer – CN 1.1 0.8 0 0 0 0.7 1.8 0.5 0 2.1 0 0 0 0.3 0 0 0.46 11
Prostate adenocarcinoma – CA 1.1 0 0 0 0 0 0 0.8 0 0 0.9 0 0 0.3 0 0 0.19 9
Kidney renal pap. cell carcinoma – TCGA, US 1.1 0 0 0 2 1.3 0.6 0 1.2 1 0 0 0 0 0 0 0.45 8
Prostate adenocarcinoma – UK 1.1 0.8 0 0 0 1.3 0.6 0 0 0 0 0.4 0 0 0 0.6 0.30 8
Early onset prostate cancer – DE 0 0.8 0 0 0 0 0.6 0 0 0 0.5 0.2 0 0 0 0.6 0.17 6
Ovarian serous cystadenoca – TCGA, US 2.2 0 1 1.1 0 0 0 0.3 1.2 0 0 0 0 0 0 0 0.36 6
Head and neck thyroid carcinoma – TCGA, US 0 0 0 0 0 0 0 0.3 0 1 0 0.4 0 0.3 0 0 0.13 5
Esophageal cancer – CN 0 0 0 0 0 0.7 0 0.3 0 0 0 0 0 0.7 0 0 0.11 4
Gastric cancer – CN 0 0.8 0 0 0 0 0 0 0 0 0 0 0 0.3 0 0.6 0.11 3
Benign liver tumor – FR 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2.1 0 0.13 2
Chronic lymphocyclic leukemia – ES 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.6 0.04 1
Total 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 3003
The numbers of TBX mutations in 38 different somatic cancer genome projects (cf. Table S1 in Supplementary Material for absolute numbers) were normalized for each of the 16 human TBX genes. TBX3 mutations and data from the 
TCGA breast cancer project are highlighted by gray shading. The total number of TBX mutations identified in different cancer projects is given in the rightmost column. These numbers vary largely due to the number of tissues analyzed 
and due to cancer-intrinsic differences in mutation rate. In the TCGA breast cancer data set, TBX3 is the most frequently mutated TBX gene.
FigUre 7 | Position of TBX3 frameshift mutations in breast cancer. The position of 16 somatic frameshift mutations identified in primary breast cancer tumors 
is indicated on a schematic drawing of TBX3 [723 amino acids (aa)]. The positions of the T-box, the nuclear localization sequence [290–295 aa, black bar adjacent 
to T-box (35)], and the C-terminal repression domain (35) are shown as gray boxes. Fifteen of 16 mutations cluster in the N-terminal half of the protein, most of them 
in the T-box.
TaBle 2 | Mutations affecting the open reading frame of TBX genes in breast cancer.
TBX gene Protein length Frame shift Missense stop gained in-frame del syn sum
EOMES 705 3 3
T 435 1 1 2 4
TBR1 682 1 2 3
TBX1 495 1 1 2
TBX2 712 1 1
TBX3 723 15 8 1 2 1 27
TBX4 545 2 1 1 4
TBX5 518 1 5 1 7
TBX6 436 0
TBX10 385 1 1 1 3
TBX15 602 4 4
TBX18 607 5 2 7
TBX19 448 1 1 2
TBX20 447 3 3
TBX21 535 2 2
TBX22 520 6 1 1 8
Sum 20 41 5 2 12 80
Average mut nr/TBX gene 1.25 2.56 0.31 0.12 0.75
The TCGA breast cancer data set was analyzed for five types of mutations affecting the open reading frame (ORF) of TBX genes. ORF length is in the second column. In the second 
but last column, synonymous codon changes (syn) are listed. The row at the bottom presents the mutation number averaged over 16 TBX genes. This allows to calculate the 
enrichment of particular mutation types in TBX3 (shaded).
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TBX19) lack the corresponding amino acid. This suggests that 
N212 is not essential for T-box function.
In the X-ray structure of the TBX3–DNA complex, T210 is 
part of the short β-strand e encompassing amino acids 208–211. 
These four amino acids are completely conserved in the T-box 
protein family (Figure  1). K208 and N211 interact with the 
target DNA both in TBX3 and in Xenopus Brachyury (76, 81). 
A structural change in this protein strand is, therefore, expected 
to have functional consequences. In TBX19, even a conserva-
tive mutation of the lysine, corresponding to K208 in TBX3, to 
arginine abolishes DNA binding and target gene activation (82). 
The mutation T209I in Tbx20 (T209 in Tbx20 corresponds to 
T210 in TBX3, see Figure 1) causes a reduction in the activation 
of an endogenous target gene in an ex vivo assay at low concen-
tration of the mutant protein. However, at high concentration 
the mutant protein is as effective as normal Tbx20 (83). In this 
respect, Tbx20–T209I and TBX3–T210delT appear similar. 
T210delT, too, reduces but does not eliminate affinity for T-box 
target sequences.
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H187 is completely conserved in the T-box protein family. 
In the TBX3/DNA structure, it lies in the β-strand C′, which is 
part of the seven-stranded β-barrel that forms the core of the 
T-domain. C′ does not contact the DNA but the H187Y mutation 
apparently changes the structure such that the mutant protein no 
longer effectively binds to target sequences. The same missense 
mutation at the corresponding position (H125Y) was identified 
in Tpit (TBX19). Tpit-H125Y does not bind to the consensus 
palindrome in EMSA and is inactive in target gene activation in 
a transfection assay (82).
repressor activity in TBX3 Mutant 
Proteins
In our transient transfection assay, the DNA-binding-deficient 
TBX3 mutants, TBX3dm (Figures  3A and 4A) and H187Y 
(Figure  4A), still caused about 40–60% repression of p21-Luc. 
Like repression by normal TBX3, this repression was dose 
dependent (Figure  3A). These findings suggest that repression 
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of p21-Luc occurs by two mechanisms. In one, TBX3 acts as 
an active, DNA-bound repressor; in the other, TBX3 is a co-
repressor. Repression by TBX2 and TBX3 largely depends on a 
C-terminal repression domain (12, 35, 36). In TBX3, this repres-
sion domain was shown to be essential for the immortalization of 
primary embryonic fibroblasts (35). Y163fs2*, which lacks DNA 
binding and repression domain, did not repress p21-Luc (Figure 
S1 in Supplementary Material). TBX2 has been reported to act 
as a co-repressor on promoter constructs of two breast cancer 
tumor suppressor genes (NDRG1 and CST6) by binding to the 
transcription factor EGR1 (24, 53). Thus, there is precedence 
for both repression mechanisms. While TBX3dm could repress 
transfected p21-Luc to some extent (Figure  4A), it completely 
failed to repress the endogenous p21 gene (Figure 5), indicating a 
higher stringency of the co-repression mechanism in the natural 
p21 chromosomal context.
Repression of p21-Luc by TBX3 mutant proteins corre-
sponded to their DNA-binding in vitro. H187Y with low DNA 
binding did not differ from the DNA-binding-deficient TBX3dm. 
The repression by T210delT with intermediate DNA binding 
was intermediate between normal TBX3 and TBX3dm, while 
N212delN, in which DNA binding was barely compromised, 
repressed nearly as strongly as normal TBX3 (Figure  4A). In 
contrast, all three point mutants were effective repressors of 
the endogenous gene indicating that, in the native chromatin 
context, a partly functional T-domain sufficed for full repression 
(Figure  5). The T-domain of T-box genes is not only required 
for DNA binding but also for protein–protein interactions. The 
interaction with many chromosomal proteins is mediated by the 
T-domain (84–91). Presumably, weak perturbations of the T-box 
still allow binding to such factors in the native chromatin context 
and, thus, effective gene repression by mutant TBX3 proteins with 
attenuated DNA binding.
somatic TBX3 Mutations in Breast cancer
Our analysis of TBX mutations in the ICGC data set showed 
that in breast cancer (BRCA-US), TBX3 was the most frequently 
mutated TBX gene among the 16 human paralogs. This is not due 
to TBX3 presenting an unusually large target size, TBX3 being 
smaller than the average TBX gene. We also reduced the target 
size effect by concentrating on the ORF, which only varies about 
twofold among the TBX genes. We noted that, over the entire set 
of somatic cancer genome projects, two types of mutations affect-
ing the ORF were significantly enriched in TBX3 compared to the 
other TBX genes: frameshift mutations and in-frame deletions 
(Table S4 in Supplementary Material). A large part of these muta-
tions arose in breast cancer (71 and 40%, respectively; compare 
Table 2 with Table S4A in Supplementary Material). Restricting 
the analysis to breast cancer revealed also a slight enrichment of 
missense mutations in TBX3 (Table 2).
Frameshifts cause a truncation of the mutant protein down-
stream of the mutation site and can be expected to be all the more 
severe, the closer the mutations lie to the N-terminus. In breast 
cancer, the frameshift mutations in TBX3 showed an extreme 
bias to the N-terminal half of the protein (Figure 7). With the 
exception of N673fs, all frameshift mutations can be expected to 
cause loss of function either by disruption of the DNA-binding 
domain or of the nuclear localization sequence (R294fs). E307fs, 
which causes a sequence change just downstream of the T-box, 
could potentially be a dominant negative mutation (5, 28, 92, 
93). We demonstrated loss of function for Y163fs2*, which 
lacked DNA binding (Figure 2C) and failed to repress p21-Luc 
(Figure S1 in Supplementary Material). In the case of missense 
mutations, conclusion with regard to residual function of the 
mutant proteins cannot be drawn as easily. The enrichment for 
mutations in conserved residues suggests that most will lead to 
loss of function.
Our experimental data with the frameshift Y163fs2*, the 
missense H187Y, and the in-frame deletion mutant proteins 
(T210delT) revealed partial or complete loss of function in vitro 
(EMSA) and in cell culture (p21-Luc repression). While this 
loss of function is in agreement with the expectations from the 
statistical analysis of TBX3 mutations in breast cancer as out-
lined above, it is in apparent contradiction to several previous 
observations on the role of TBX3 in oncogenesis. In general, it 
was overexpression of TBX3, which was found associated with 
oncogenic processes at the organismic, cellular, and gene regu-
latory level. This we outline in the following mainly for breast 
cancer and melanoma but similar findings were made for other 
types of cancer (27, 94–98).
TBX3 was reported to be overexpressed in breast cancer cell 
lines and in primary cancer tissue (37, 79). An increased level of 
TBX3 was observed in blood plasma from patients with higher 
stage breast cancer (99). Similarly, increased expression of TBX3 
was seen in melanoma cell lines (4) where TBX3 represses 
E-cadherin expression and causes increased invasiveness (6, 17, 
18) and tumor formation in vivo (100). A critical role of TBX3 for 
cell migration was also demonstrated in the MCF7 breast cancer 
cell line (17, 101).
TBX3 expression also antagonizes replicative and oncogenic 
senescence by repressing p14(ARF). This was demonstrated 
with a conditionally transformed mouse neuronal cell line (13) 
and with primary mouse fibroblasts (16, 35) but not yet, to our 
knowledge, with mammary cells.
TBX3 promotes growth of mammary epithelial cells both in 
cell culture (26) and in a transgenic mouse where it causes mam-
mary hyperplasia in the absence of tumor formation (21). In 
human breast cancer cell lines and primary tissue, TBX3 mediates 
the effect of estrogen to induce the formation and expansion of 
cancer stem-like cells (20). The effect on proliferation is, however, 
dependent on cell type. In the breast cancer cell line MCF-7 and in 
vertical growth phase melanoma cell lines, both of which express 
TBX3 endogenously, it is knock-down of TBX3 that promotes 
proliferation (17). A similar phenomenon we observed for the 
TBX3 ortholog Omb in the wing imaginal disk of Drosophila, 
where Omb overexpression antagonizes proliferation in regions 
of high endogenous Omb and promotes proliferation in regions of 
low endogenous Omb (and vice versa). Omb overexpression leads 
to invasive cell motility in all regions of the disk epithelium (51).
Among the TBX3 mutants that we analyzed, only N212delN 
was not significantly compromised with regard to DNA binding 
and p21 repression, compared to normal TBX3. Rather, N212delN 
showed an aspect of gain-of-function: N212delN had higher 
transcript and protein abundance compared to normal TBX3. 
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The N211-N212 doublet, encoded by tandem AAC codons, may 
be susceptible to slippage defects during replication or repair, 
such that N212delN may arise as a neutral mutation in cells under 
genomic stress.
The focus of this work was to study the impact of TBX3 muta-
tions as they were identified in primary breast cancers on the 
transcriptional properties of the protein. For the investigation 
of cell biological properties relevant to carcinogenesis, such as 
proliferation, motility, and invasive growth, the mutations will 
have to be studied in appropriate cancer cell lines.
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